FREQUENCY OF MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH DE NOVO CORONARY ARTERY DISEASE REVASCULARIZED WITH EVEROLIMUS-ELUTING STENTS

Authors

  • Syed Tahir Shah
  • Ibrahim Shah
  • Sami Ullah
  • Noor ul Hadi
  • Hikmatullah Jan
  • Adnan Mehmood Gul
  • Mohammad Hafizullah

DOI:

https://doi.org/10.47144/phj.v50i4.1366

Abstract

Objective: The aim of this study was to determine the frequency of major adversecardiac events in patients with de novo coronary artery disease revascularizedwith everolimus-eluting stents.

Methodology: This prospective cross sectional study was carried out in thedepartment of cardiology, Lady Reading Hospital Peshawar from October 2011to November 2012. Patients with de novo coronary artery disease, who wererevascularized with everolimus-eluting stents, were included in the study. Theirbaseline clinical and procedural characteristics were recorded from hospitalrecord. Data regarding MACE defined as composite of myocardial infarction,stent thrombosis, recurrence of ischemia and death were obtained on follow up.

Result: A total of 420 patients were included in the study in which 320(76.2%)were male. Risk factors for coronary artery disease were; diabetes mellitus147(35%), hypertension 256(61%), hypercholesterolemia 147(35%) andsmoking 100(23.8%). Most of patients had stable angina 285(67.9%). Oncoronary angiography, 98(23.3%) of patients had single vessel disease,152(36.2%) had two vessel disease and 170(40.5%) had three vessel disease.Left anterior descending artery was most frequently affected vessel 242(57.6%).Mean lesion length was 25±8.1 mm. Mean stent length/lesion was 26.03±7.09mmwhile mean stent diameter/lesion was 3.14±0.29mm. Tirofiben (Agrastate)was used in 19(4.5%) of patients.On follow up, MACE occurred in 16(3.8%) patients, 6(1.4%) patients developedmyocardial infarction, 5(1.2%) developed recurrence of ischemia, 6(1.4%) ofpatients developed stent thrombosis and 6(1.4%) of patients died during studyperiod.

Conclusion: Everolimus-eluting stents carries a lower risk of major adversecardiac events in patients with de novo coronary disease.

Key Words: Major adverse cardiac events, De novo coronary artery disease,Everolimus-eluting stents.

Downloads

Download data is not yet available.

Downloads

How to Cite

1.
Shah ST, Shah I, Ullah S, Hadi N ul, Jan H, Gul AM, Hafizullah M. FREQUENCY OF MAJOR ADVERSE CARDIAC EVENTS IN PATIENTS WITH DE NOVO CORONARY ARTERY DISEASE REVASCULARIZED WITH EVEROLIMUS-ELUTING STENTS. Pak Heart J [Internet]. 2018Mar.20 [cited 2024Nov.24];50(4). Available from: https://pakheartjournal1.pcs.org.pk/index.php/pk/article/view/1366

Issue

Vol. 50 No. 4 (2017): Pakistan Heart Journal

Section

Original Article

License

When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.

Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/